Effect of Azilsartan on Aldosterone in Postmenopausal Females
The purpose of the research is to evaluate the effect of azilsartan medoximil on blood pressure and urinary aldosterone levels in postmenopausal females.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||Effect of Azilsartan on Aldosterone in Postmenopausal Females|
- To evaluate the effect of an angiotensin receptor blocker (azilsartan medoximil) on blood pressure in postmenopausal females. [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
- To evaluate the effect of an angiotensin receptor blocker (azilsartan medoximil) on urinary aldosterone levels in postmenopausal females. [ Time Frame: 26 weeks ] [ Designated as safety issue: No ]
|Study Start Date:||January 2013|
|Estimated Study Completion Date:||January 2018|
|Estimated Primary Completion Date:||January 2018 (Final data collection date for primary outcome measure)|
Active Comparator: azilsartan medoximil.
Subjects randomized to azilsartan medoximil arm will take 80 mg of azilsartan medoximil tablets by mouth each day.
|Drug: Azilsartan medoximil|
Placebo Comparator: Placebo
Subjects randomized to the placebo arm will take 80 mg of placebo tablets by mouth each day
The study is a randomized, placebo-controlled trial of 40 post-menopausal females with stage 1 hypertension
|Contact: Carrie Schlafferemail@example.com|
|United States, Illinois|
|University of Chicago||Recruiting|
|Chicago, Illinois, United States, 60637|
|Principal Investigator:||George Bakris, MD||University of Chicago|